Catalina Olaru-Stavila

Mrs. Catalina Olaru-Stavila

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
COCatalina Olaru-Stavila
Catalina Olaru-Stavila
SSSara Martina Steinmann
Sara Martina Steinmann
PMPatricia Mester
Patricia Mester
MMMartina Müller-Schilling
Martina Müller-Schilling
ETEugen Tcaciuc
Eugen Tcaciuc
KGKarsten Gülow
Karsten Gülow
The gastrointestinal (GI) barrier is a highly coordinated, multilayered defence system that maintains intestinal homeostasis by separating the luminal microbiota from the internal milieu. In liver cirrhosis, this barrier undergoes profound structural and functional disruption, emerging as a central driver of bacterial translocation and infection-related complications. Among these, spontaneous bacterial peritonitis (SBP) represents a major determinant of morbidity, mortality, and disease progression. Barrier failure in cirrhosis is not attributable to a single defect but results from the convergence of multiple interconnected mechanisms. Structural alterations include disruption of epithelial tight junctions and deterioration of the mucus layer, leading to increased intestinal permeability and loss of spatial compartmentalisation. These changes are compounded by microbial dysbiosis, characterised by reduced diversity, depletion of short-chain fatty acid-producing taxa, and expansion of pathobionts. In parallel, cirrhosis-associated immune dysfunction impairs both mucosal and systemic antimicrobial defences, while gut–vascular barrier disruption facilitates systemic dissemination of bacteria and microbial products. The resulting increase in bacterial translocation plays a pivotal role in the pathogenesis of SBP and contributes to systemic inflammation, circulatory dysfunction, and acute decompensation. Importantly, this process establishes a self-amplifying pathogenic loop in which barrier dysfunction, dysbiosis, and immune dysregulation mutually reinforce each other. Recent advances have identified key molecular pathways involved in barrier regulation, including bile acid–FXR signalling and microbiome-derived metabolites, providing novel targets for therapeutic intervention. While current management relies largely on antibiotics and supportive care, emerging strategies aim to restore barrier integrity and modulate the gut–liver axis. A deeper understanding of GI barrier dysfunction offers new opportunities to prevent bacterial translocation and improve clinical outcomes in patients with liver cirrhosis.

8 April 2022 in Medicine and Pharmacy Reports
Verified
Journal Article
Open access
ETEugen Tcaciuc
Eugen Tcaciuc
COCatalina Olaru-Stavila
Catalina Olaru-Stavila
ZAZinaida Alexa
Zinaida Alexa
ATAngela Tcaciuc
Angela Tcaciuc
DADenis Ardeleanu
Denis Ardeleanu
Gastrointestinal manifestations in COVID-19 have been frequently acknowledged by clinicians and scientists. However, their clinical significance and potential influence on the disease outcome is not entirely elucidated. In this study we aim to evaluate gastrointestinal involvement, both digestive symptoms and liver-related changes in hospitalized COVID-19 patients in correlation to the presence or absence of underlying liver disease and rate of mortality. We performed a retrospective cohort study of COVID-19 patients, consecutively admitted in a hospital from Chisinau, between September 3, 2020 and May 31, 2021. Data on clinical symptoms and laboratory findings were collected from electronic clinical records. The cohort was divided into two groups, with and without pre-existing liver disease. The Fisher exact, Pearson Chi-square tests were used to compare groups. A total of 1835 patients were included, 108 (5.9%) with pre-existing liver disease and 1727 (94.1%) without this comorbidity. Digestive symptoms were reported by 331(18%) of the patients, diarrhea being the most common symptom 11.8% (217) and being encountered more in patients with underlying chronic liver disease. No statistical difference was identified between the groups in regard to other symptoms, comorbidities and rate of mortality. But patients with chronic liver disease had significant (P < 0.001) lower ferritin, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in comparison with the other group. At admission, 341 (19.2%) had increased aspartate aminotransferase level (AST) and 317 (17.8%) alanine aminotransferase. The enzyme abnormalities were predominantly mild and transitory. Abnormal AST level at admission and during follow up, higher ESR, CRP, ferritin, lactate dehydrogenase (LDH) was found to correlate with higher rates of mortality. Digestive implications, especially diarrhea in COVID-19 patients is frequent, but do not appear to be associated with mortality. Elevated liver enzymes during hospitalization, age, high ferritin, CRP, LDH might be interpreted as risk factors for mortality in COVID-19 but further studies are needed to address this topic.

1 December 2024 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
ETEugen Tcaciuc
Eugen Tcaciuc
COCatalina Olaru-Stavila
Catalina Olaru-Stavila
ATAngela Tcaciuc
Angela Tcaciuc
LALilian Antoci
Lilian Antoci
MCMircea Cernat
Mircea Cernat
MSMargareta Surlari
Margareta Surlari
Introduction. MALT lymphoma is the most common type of extranodal non-Hodgkin lymphoma. In two-thirds of cases, it originates in the stomach and is strongly associated with Helicobacter pylori infection. It presents a complex clinical picture, that can resemble multiple conditions, and typically follows a benign course. Clinical case presentation. This report discusses an uncommon case of a 52-year-old female who presented to the oncologist with insignificant weight loss, episodes of melena and fatigue. The disease started in 2018 with upper gastrointestinal bleeding from a gastric ulcer caused by H. pylori, which was later eradicated. The patient underwent multiple upper endoscopies over the years, with no evidence of malignancy. During the most recent investigation, an ulcerated mass of about 20 mm with infiltration of the adjacent mucosa was found. The biochemical and serological examination was within normal values. Abdominal computed tomography revealed unexplained perigastric and intestinal lymphadenopathy. The patient underwent total gastrectomy and lymph node dissection due to suspected gastric cancer. Histological and immunohistochemical examinations confirmed advanced MALT lymphoma with tumour cells positive for cluster of differentiation 45, 20 (CD45, CD20) and B-cell lymphoma 2 (BCL2). Given the advanced stage of the disease, adjuvant polychemotherapy was also administered, and the patient’s condition improved significantly. Conclusions. MALT lymphoma is a rare condition that requires close attention and a high index of suspicion, even in unusual cases like the one presented. Endoscopic examination performed by an experienced specialist, accompanied by proper biopsy and a multidisciplinary team approach increases the survival rate of patients.

1 December 2025 in Public Health, Economy and Management in Medicine
Verified
Journal Article
Open access
ETEugen Tcaciuc
Eugen Tcaciuc
EBElina Berliba
Elina Berliba
COCatalina Olaru-Stavila
Catalina Olaru-Stavila
MOMariana Ous-Cebotar
Mariana Ous-Cebotar
ABAna Maria Badarau
Ana Maria Badarau
Sarcoidosis is a systemic inflammatory disease of unknown etiology that may, in atypical cases, involve the liver. Hepatic manifestations are often subtle, heterogeneous, and nonspecific, which can mislead clinicians and delay an accurate diagnosis. Liver biopsy with histological examination remains the gold standard for diagnosis, playing a critical role in confirming hepatic sarcoidosis. We report the case of a 43-year-old female patient admitted to the hepatology department with persistent right upper quadrant pain and fatigue. Biochemical analysis revealed a cytolytic and cholestatic pattern, while complete blood count showed anemia and thrombocytosis. Viral, tumor, and autoimmune liver markers were within reference ranges. Abdominal ultrasound and computed tomography (CT) revealed hepatomegaly. Hematologic malignancies were ruled out. The diagnosis of hepatic sarcoidosis was established by histopathological examination of a liver biopsy. Considering the frequent association with pulmonary sarcoidosis, a thoracic CT scan was performe which revealed mediastinal lymphadenopathy. The patient was subsequently referred to the pulmonology team, where immunosuppressive therapy was initiated, with favorable clinical and laboratory evolution. This case highlights an unusual presentation of hepatic involvement in systemic sarcoidosis. It underscores the importance of a multidisciplinary approach to achieve timely diagnosis and initiate appropriate pathogenetic treatment, particularly in the presence of unexplained hepatic abnormalities.

1 December 2025 in Public Health, Economy and Management in Medicine
Verified
Journal Article
Open access
PDF file
ETEugen Tcaciuc
Eugen Tcaciuc
EBElina Berliba
Elina Berliba
MOMariana Ous-Cebotar
Mariana Ous-Cebotar
COCatalina Olaru-Stavila
Catalina Olaru-Stavila
NCNicoleta Costin
Nicoleta Costin
FSFelicia Secrieru
Felicia Secrieru
Biliary hamartomas are benign hepatic malformations scattered throughout the parenchyma, which are usually asymptomatic. However, the diagnostic dilemmas they may cause justify the need for their thorough investigation. The aim of this article is to present the clinical case of a 55-year-old man with biliary hamartomas who was initially misdiagnosed with hepatic fibrosis based on elastography findings. For this purpose we used patient’s medical records, laboratory tests, imaging studies, and histopathological evaluations. The symptoms that led the patient to seek medical attention were very nonspecific: abdominal discomfort, bloating, and general fatigue. Paraclinical assessments remained inconclusive for a long time, suggesting progressive liver fibrosis. However, histopathological examination of hepatic tissue revealed no signs of fibrosis but confirmed the presence of biliary hamartomas, which were found to be the cause of the previous overestimation of fibrosis. Subsequently, contrast-enhanced magnetic resonance cholangiopancreatography was performed to assess the size (less than 4 mm) and hepatic distribution (segments VI and VIII) of the hamartomas. These findings allow us to conclude that biliary hamartomas are small hepatic lesions that rarely have a significant impact on the patient’s health, but their identification can be challenging due to the nonspecific clinical presentation and equivocal imaging features. Once diagnosed, careful monitoring is essential due to the potential risk of malignant transformation.

1 December 2025 in Public Health, Economy and Management in Medicine
Verified
Journal Article
Open access
PDF file
ETEugen Tcaciuc
Eugen Tcaciuc
COCatalina Olaru-Stavila
Catalina Olaru-Stavila
APAggarwal Pranjal
Aggarwal Pranjal
Boala de reflux gastroesofagian (BRGE) și diabetul zaharat de tip 2 (DZT2) se numără printre cele mai răspândite afecțiuni cronice la nivel global. Acest studiu își propune să sintetizeze descoperirile recente privind asocierea dintre BRGE și DZT2, cu accent pe potențialul abordărilor terapeutice integrate. A fost efectuată o analiză narativă utilizând literatura de specialitate națională și internațională publicată, cu aplicarea motorului de căutare din PubMed, Scopus și EMBASE. Studiile recente evidențiază o interacțiune bidirecțională între BRGE și DZT2, ceea ce contribuie la exacerbarea reciprocă a acestor patologii și rezultate suboptimale la tratament. DZT2 predispune la BRGE prin neuropatie autonomă, golire gastrică întârziată și motilitate esofagiană alterată. În schimb, BRGE afectează glicemia prin aderența slabă la tratament, motivată fiind de simptomele chinuitoare nocturne. Obezitatea, dimicrobismul intestinal și adipokinele proinflamatorii leagă în continuare ambele patologii. În ciuda recomandărilor ample stipulate de ghiduri, screeningul pentru BRGE la diabetici și viceversa nu este standardizat și efectuat sporadic. Atenția specialiștilor ar trebui îndreptată spre diagnosticul precoce folosind instrumente validate și intervenții terapeutice comune precum gestionarea țintită a greutății și terapii cu dublă utilizare. Agenții farmacologici inovatori, cum ar fi agoniștii receptorilor GLP-1 și terapiile direcționate către microbiotă, sunt promițători pentru gestionarea ambelor boli. Legătura bidirecțională dintre BRGE și DZT2 reflectă mecanisme fiziopatologice comune, care necesită o schimbare importantă către modele de îngrijire integrată. Colaborarea dintre gastroenterologi, endocrinologi și medicii de familie este esențială.